BioCentury | Aug 8, 2020
Product Development

Bringing COVID-19 vaccines to authorization faster through data sharing

Developers of leading COVID-19 vaccines won’t be able to meet global demand on their own, but they do have the power to accelerate global coverage by helping each other reach authorization and streamlining development for...
BioCentury | Aug 6, 2020
Regulation

GSK first across finish line in closely watched BCMA race

Despite toxicity concerns, FDA approved GSK’s BCMA-targeted antibody-drug conjugate Blenrep late Wednesday, making it the first in a new class of drugs for multiple myeloma. The accelerated approval for GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) didn’t come...
BioCentury | Aug 4, 2020
Product Development

Warp Speed, decentralized trials & SPACs: a BioCentury podcast

After pledging up to $2.1 billion to a preclinical vaccine from Sanofi and GSK, the U.S. government’s total commitment for COVID-19 vaccine candidates now stands at $8.3 billion across seven vaccines based on four different...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer DGAT1 inhibition could treat glioblastoma multiforme (GBM) by promoting fat catabolism. Levels of triglycerides and lipid droplets were higher in postmortem brain tissue from GBM patients than individuals without...
BioCentury | Jul 31, 2020
Product Development

Warp Speed’s $2.1B commitment to Sanofi-GSK COVID-19 program brings total to $8.3B across seven vaccines

A preclinical vaccine from Sanofi and GSK may be months behind other COVID-19 vaccines in development, but the U.S. government has made its largest financial commitment yet to its development and manufacturing, pledging up to...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fifth for COVID-19

As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi on Wednesday checks the recombinant protein vaccine box. The product has yet to enter the...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

Omega reveals venture tally  Omega Therapeutics Inc. announced it has raised $85 million since its 2016 launch by Flagship Pioneering to support development of therapies targeting chromatin structures. The funding includes a series A round...
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin. FDA’s Oncologic Drugs Advisory Committee unanimously...
BioCentury | Jul 23, 2020
Finance

Amid measured expansion, Longwood raises $170M for fifth fund

Although Longwood Fund’s latest vehicle is more than twice the size of its prior fund, the 10-year-old firm doesn’t expect to stray far from its strategy of launching start-ups with syndicated early rounds. The new...
Items per page:
1 - 10 of 8830
BioCentury | Aug 8, 2020
Product Development

Bringing COVID-19 vaccines to authorization faster through data sharing

Developers of leading COVID-19 vaccines won’t be able to meet global demand on their own, but they do have the power to accelerate global coverage by helping each other reach authorization and streamlining development for...
BioCentury | Aug 6, 2020
Regulation

GSK first across finish line in closely watched BCMA race

Despite toxicity concerns, FDA approved GSK’s BCMA-targeted antibody-drug conjugate Blenrep late Wednesday, making it the first in a new class of drugs for multiple myeloma. The accelerated approval for GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) didn’t come...
BioCentury | Aug 4, 2020
Product Development

Warp Speed, decentralized trials & SPACs: a BioCentury podcast

After pledging up to $2.1 billion to a preclinical vaccine from Sanofi and GSK, the U.S. government’s total commitment for COVID-19 vaccine candidates now stands at $8.3 billion across seven vaccines based on four different...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer DGAT1 inhibition could treat glioblastoma multiforme (GBM) by promoting fat catabolism. Levels of triglycerides and lipid droplets were higher in postmortem brain tissue from GBM patients than individuals without...
BioCentury | Jul 31, 2020
Product Development

Warp Speed’s $2.1B commitment to Sanofi-GSK COVID-19 program brings total to $8.3B across seven vaccines

A preclinical vaccine from Sanofi and GSK may be months behind other COVID-19 vaccines in development, but the U.S. government has made its largest financial commitment yet to its development and manufacturing, pledging up to...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fifth for COVID-19

As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi on Wednesday checks the recombinant protein vaccine box. The product has yet to enter the...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

Omega reveals venture tally  Omega Therapeutics Inc. announced it has raised $85 million since its 2016 launch by Flagship Pioneering to support development of therapies targeting chromatin structures. The funding includes a series A round...
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin. FDA’s Oncologic Drugs Advisory Committee unanimously...
BioCentury | Jul 23, 2020
Finance

Amid measured expansion, Longwood raises $170M for fifth fund

Although Longwood Fund’s latest vehicle is more than twice the size of its prior fund, the 10-year-old firm doesn’t expect to stray far from its strategy of launching start-ups with syndicated early rounds. The new...
Items per page:
1 - 10 of 8830